Migraine biotech Vedana Therapeutics makes its debut with $46M Series A
Vedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraine...
Vedana Therapeutics has emerged from stealth with $46 million in Series A proceeds with the goal of developing treatments that could free patients from migraines entirely. Available treatments for migraine typically only reduce attack frequencies ...